Nirmal Bang

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

A Relationship Beyond Broking

External broker reports(aggregated public sources), Nirmal Bang

External broker reports(aggregated public sources)

Equity Bottom-Up

<div><div><div><div><ul><li>Investing in dominant brands: Sanofi India has been relying on the growth of dominant brands like Lantus, Toujeo, Amaryl and Allegra in the domestic portfolio.</li></ul><div><div><div><ul><li>We currently assume Lantus to come under DPCO: While the new NLEM list is yet to be finalized and there is a probability that Lantus may be included in the same.</li></ul><div><div><div><div><ul><li>Potential introduction of other insulin products in India: Sanofi’s parent company has received approval for the biosimilar version of other insulin brands in regulated markets and we believe the company would look to introduce these biosimilar versions in India too.</li></ul></div></div></div></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Investing in dominant brands: Sanofi India has been relying on the growth of dominant brands like Lantus, Toujeo, Amaryl and Allegra in the domestic portfolio.We currently assume Lantus to come under DPCO: While the new NLEM list is yet to be finalized and there is a probability that Lantus may be included in the same.Potential introduction of other insulin products in India: Sanofi’s parent company has received approval for the biosimilar version of other insulin brands in regulated markets and we believe the company would look to introduce these biosimilar versions in India too.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sanofi India - Beat on Margins; Strong Recovery Sequentially